Episode 10: Ivosidenib - The Backstory
Type: Individual•Format: On-demand
Upon completion of this activity, participants will be able to:
- Articulate the reasoning behind an FDA oncology drug approval.
- Identify the relevant sections of the drug USPI where information is located.
- Integrate this information into their clinical practice.
Review video content here.
Time to Complete Activity:
Get It
In This Episode:
- Kelly Norsworthy, MD, Deputy Division Director, Division of Hematologic Malignancies 1, Office of Oncologic Diseases, FDA Center for Drug Evaluation and Research
- Ashley Woods, MD, Hematologist, Division of Hematologic Malignancies 1, Office of Oncologic Diseases, FDA Center for Drug Evaluation and Research
- Susan Pandya, MD, Vice President, Clinical Development, Head of Cancer Metabolism Global Division, Servier Pharmaceuticals
- Stéphane de Botton, MD, PhD, Physician, Clinical Investigator, Head of Hematology, Gustave Roussy Cancer Center
- Amir Fathi, MD, Director of Leukemia Program, Massachusetts General Hospital
- Aura Ramos, RN, BSN, Research Nurse, Massachusetts General Hospital
- Matthew Newman, PharmD, Oncology Pharmacist, Johns Hopkins University
- Lucille Giunta, Patient and Clinical Trial Participant
Get It
Disclosure Statement
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed all financial relationships they have with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products or services used by or on patients. All of the relevant financial relationships listed for these individuals have been mitigated.